Physician profile
Thandiwe C Gray
NPI 1194884338
$2,360.63
in general payments reported to CMS, 2019-2025
51 companies · $770 in 2025
The $770 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $68.95 · 2021: $13.93 · 2022: $31.46 · 2023: $489 · 2024: $600 · 2025: $770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,675 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,675.26 |
| Education | $183.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $200.22 | 2019-2025 | Carvykti, Darzalex, Talvey |
| Astrazeneca Pharmaceuticals Lp | $198.69 | 2019-2025 | Enhertu |
| Exelixis INC. | $151.89 | 2019-2024 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $135.86 | 2019-2025 | |
| Sobi, INC | $99.99 | 2025 | |
| Glaxosmithkline, LLC. | $98.70 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Pfizer INC. | $98.14 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $79.77 | 2019-2025 | Keytruda, Welireg |
| Eisai INC. | $79.15 | 2020-2025 | |
| Abbvie INC. | $78.60 | 2019-2025 | |
| Celgene Corporation | $66.30 | 2019-2024 | Opdualag, Pomalyst |
| Puma Biotechnology, INC. | $66.20 | 2024-2025 | |
| Daiichi Sankyo INC. | $65.00 | 2019-2025 | Datroway, Enhertu, Injectafer |
| Incyte Corporation | $56.82 | 2019-2024 | Jakafi, Monjuvi, Zynyz |
| Regeneron Healthcare Solutions, INC. | $53.16 | 2023-2024 | Libtayo |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thandiwe Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.